BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 26608331)

  • 21. Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development.
    Balligand T; Achouri Y; Pecquet C; Gaudray G; Colau D; Hug E; Rahmani Y; Stroobant V; Plo I; Vainchenker W; Kralovics R; Van den Eynde BJ; Defour JP; Constantinescu SN
    Leukemia; 2020 Feb; 34(2):510-521. PubMed ID: 31471561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN.
    Benlabiod C; Cacemiro MDC; Nédélec A; Edmond V; Muller D; Rameau P; Touchard L; Gonin P; Constantinescu SN; Raslova H; Villeval JL; Vainchenker W; Plo I; Marty C
    Nat Commun; 2020 Sep; 11(1):4886. PubMed ID: 32985500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The MPL mutation.
    Guglielmelli P; Calabresi L
    Int Rev Cell Mol Biol; 2021; 365():163-178. PubMed ID: 34756243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High resolution melting analysis: a rapid and accurate method to detect CALR mutations.
    Bilbao-Sieyro C; Santana G; Moreno M; Torres L; Santana-Lopez G; Rodriguez-Medina C; Perera M; Bellosillo B; de la Iglesia S; Molero T; Gomez-Casares MT
    PLoS One; 2014; 9(7):e103511. PubMed ID: 25068507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants.
    Salati S; Genovese E; Carretta C; Zini R; Bartalucci N; Prudente Z; Pennucci V; Ruberti S; Rossi C; Rontauroli S; Enzo E; Calabresi L; Balliu M; Mannarelli C; Bianchi E; Guglielmelli P; Tagliafico E; Vannucchi AM; Manfredini R
    Sci Rep; 2019 Jul; 9(1):10558. PubMed ID: 31332222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.
    Araki M; Komatsu N
    Cancer Sci; 2017 Oct; 108(10):1907-1912. PubMed ID: 28741795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L.
    Taksin AL; Couedic JP; Dusanter-Fourt I; Massé A; Giraudier S; Katz A; Wendling F; Vainchenker W; Casadevall N; Debili N
    Blood; 1999 Jan; 93(1):125-39. PubMed ID: 9864154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
    Turakhia SK; Murugesan G; Cotta CV; Theil KS
    J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Megakaryocytes in Myelofibrosis.
    Melo-Cardenas J; Migliaccio AR; Crispino JD
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):191-203. PubMed ID: 33641863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value.
    Vannucchi AM; Rotunno G; Bartalucci N; Raugei G; Carrai V; Balliu M; Mannarelli C; Pacilli A; Calabresi L; Fjerza R; Pieri L; Bosi A; Manfredini R; Guglielmelli P
    Leukemia; 2014 Sep; 28(9):1811-8. PubMed ID: 24618731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
    Rumi E; Pietra D; Pascutto C; Guglielmelli P; Martínez-Trillos A; Casetti I; Colomer D; Pieri L; Pratcorona M; Rotunno G; Sant'Antonio E; Bellini M; Cavalloni C; Mannarelli C; Milanesi C; Boveri E; Ferretti V; Astori C; Rosti V; Cervantes F; Barosi G; Vannucchi AM; Cazzola M;
    Blood; 2014 Aug; 124(7):1062-9. PubMed ID: 24986690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Development of myeloproliferative neoplasms by mutant calreticulin: underlying mechanisms].
    Araki M
    Rinsho Ketsueki; 2018; 59(8):1072-1077. PubMed ID: 30185708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
    Loghavi S; Bueso-Ramos CE; Kanagal-Shamanna R; Ok CY; Salim AA; Routbort MJ; Mehrotra M; Verstovsek S; Medeiros LJ; Luthra R; Patel KP
    Am J Clin Pathol; 2016 Mar; 145(3):418-27. PubMed ID: 27124925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Presence of calreticulin mutations in JAK2-negative polycythemia vera.
    Broséus J; Park JH; Carillo S; Hermouet S; Girodon F
    Blood; 2014 Dec; 124(26):3964-6. PubMed ID: 25305205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.
    Edahiro Y; Araki M; Komatsu N
    Cancer Sci; 2020 Aug; 111(8):2682-2688. PubMed ID: 32462673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism.
    Garbati MR; Welgan CA; Landefeld SH; Newell LF; Agarwal A; Dunlap JB; Chourasia TK; Lee H; Elferich J; Traer E; Rattray R; Cascio MJ; Press RD; Bagby GC; Tyner JW; Druker BJ; Dao KH
    Am J Hematol; 2016 Feb; 91(2):211-9. PubMed ID: 26573090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Germline MPL mutations may be a rare cause of "triple-negative" thrombocytosis.
    Borsani O; Pietra D; Casetti IC; Vanni D; Riccaboni G; Catricalà S; Grazia B; Boveri E; Arcaini L; Rumi E
    Exp Hematol; 2024 Jan; 129():104127. PubMed ID: 37939832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of calreticulin mutations in myeloproliferative neoplasms.
    Araki M; Komatsu N
    Int J Hematol; 2020 Feb; 111(2):200-205. PubMed ID: 31848992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.
    Di Buduo CA; Abbonante V; Marty C; Moccia F; Rumi E; Pietra D; Soprano PM; Lim D; Cattaneo D; Iurlo A; Gianelli U; Barosi G; Rosti V; Plo I; Cazzola M; Balduini A
    Blood; 2020 Jan; 135(2):133-144. PubMed ID: 31697806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.